CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Summary

This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs. placebo on clinical outcomes of type 2 diabetes.

Timeline

Start

2017-01-05

Primary completion

2018-07-19

Completion

2018-07-19

Outcome

Outcome not reported

Stopped (Enrollment): “Study was terminated due to difficulty with reaching enrollment goals”

Drugs

Indications